The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities (Q37766229)

22 August 2017

1 reference

title

The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities (English)

1 reference

22 August 2017

0 references

1 reference

Gérald E Piérard

1

1 reference

22 August 2017

Claudine Piérard-Franchimont

2

1 reference

22 August 2017

Grégory Szepetiuk

3

1 reference

22 August 2017

Philippe Paquet

4

1 reference

22 August 2017

Pascale Quatresooz

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

1197-1208

1 reference

Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Pathogenesis and therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Immunopathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Regulation of IL-17 in human CCR6+ effector memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The biological functions of T helper 17 cell effector cytokines in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

A rush to judgment on Th17

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The cytokine and chemokine network in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The risk of mortality in patients with psoriasis: results from a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

EEMCO guidance for the assessment of hair shedding and alopecia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Altered bone remodeling in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Connections between psoriasis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Psoriasis associated with ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adipocyte-derived hormones, cytokines, and mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Heart disease in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Chronic plaque psoriasis is associated with increased arterial stiffness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Arterial stiffness as a risk factor for coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Psoriasis: a possible risk factor for development of coronary artery calcification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Update on the mechanisms and efficacy of biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Alopecia areata following adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Improved survival in psoriatic arthritis with calendar time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Increased Sensitivity to Interferon-α in Psoriatic T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Vasculitis induced by tumor necrosis factor-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab treatment for severe recalcitrant chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab: in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

The emerging role of pharmacogenomics in biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.500283

10.1517/14712598.2010.500283

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference